Below is a text only representation of the Patient Information Leaflet (ePIL).
The text only version may be available in large print, Braille or audio CD.
For further information call emc accessibility on
0800 198 5000.
The product code(s) for this leaflet is: PL 10590/0047.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet:
1. What Silkis is and what it is used for 2. What you need to know before you use Silkis 3. How to use Silkis 4. Possible side effects 5. How to store Silkis 6. Contents of the pack and other information
1. What Silkis is and what it is used for
Silkis is used for the topical treatment of mild to moderately severe plaque psoriasis with up to one third of body surface area involvement.
It contains an active ingredient, calcitriol (a vitamin D derivate), which inhibits and normalizes the unrestrained cell growth in psoriasis affected skin.
2. What you need to know before you use Silkis
Do not use Silkis:
if you are treated by systemic (oral) route for a calcium deficiency
if you have a kidney or liver disease
if you have high blood calcium levels or if you suffer from abnormal calcium metabolism
if you are allergic to calcitriol or to any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor or pharmacist before using Silkis.
Carefully apply the ointment to the face, since it has a greater risk of irritation. Avoid contact with the eyes.
After using the ointment, wash your hands to prevent unintentional spread to non-affected zones.
Due to a potential effect on calcium metabolism, the ointment may not be applied under an occlusive wound dressing.
In case of severe irritation or allergic reaction occur, the treatment should be discontinued and the doctor contacted.
Although no significant hypercalcaemia (high blood calcium levels) was observed during clinical studies with this ointment, there is some absorption of calcitriol by the skin. This gives a risk of an increase of blood or urine calcium levels. This risk is minimal if you follow your doctor's advice.
Do not smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.'
Children
There is limited data on the use of Silkis in children. Therefore, use in children should be avoided.
Other medicines and Silkis
Silkis might interfere with other medicines such as:
Thiazide diuretics as their use jointly with this medicine would increase your blood calcium levels.
Medications whose action can be modified by a change in calcium blood level such as digoxin
Calcium supplements or high doses of vitamin D.
Peeling agents, astringent agents or irritant agents, because additional irritant effects might occur.
Inform your doctor of any other topical treatment you may have used or you are using for your psoriasis lesions, before starting this treatment.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Silkis should not be used if you are breast-feeding.
Driving and using machines:
The treatment does not affect the ability to drive and use machines.
3. How to use Silkis
Silkis is an ointment for use on the skin only (cutaneous).
Always use this medicine exactly as your doctor has told you.
Check with your doctor or pharmacist if you are not sure.
Dosage instructions
First wash and dry the affected areas of your skin.
Apply a thin layer of Silkis over the affected areas to be treated twice a day, morning and evening before retiring, or as advised by your doctor.
Wash your hands after each application in order to avoid any contact with other non lesional areas.
Do not use more than 30 g of ointment per day and do not cover more than one third of your skin area (approximately one full arm and one full leg).
Do not swallow this product. If you accidentally do so, seek immediate medical advice.
Regularly follow your treatment, according strictly to your doctor's instructions.
If you feel that the effect of this medicine is too strong or too weak, talk to your doctor or pharmacist.
If you use more Silkis than you should:
If the product is applied excessively, no more rapid or better results will be obtained and marked redness, peeling or discomfort may occur.
Always contact your physician to hear whether treatment or discontinuation is necessary if too much Silkis is used.
Hypotonia (decreased tension in muscles), nausea, vomiting, lack of appetite, constipation and depression may occur after using too much calcitriol. Therefore, contact your physician if these symptoms appear.
If you forget to use Silkis:
Do not apply a double dose to make up for forgotten individual doses.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
In case of severe irritation or contact allergy (redness, itching), the treatment should be stopped and the patient should seek medical attention. If contact allergy is confirmed, the treatment should be discontinued.
This medicine may cause some unwanted effects at the site of application:
Common (may affect up to 1 in 10 people)
pruritus (itching skin)
skin discomfort
skin irritation
erythema (skin redness)
Uncommon (may affect up to 1 in 100 people)
dry skin
psoriasis aggravation
Not known (frequency cannot be estimated from the available data)
skin oedema
contact dermatitis
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Silkis
Keep out of the sight and reach of children.
Discard the tube 8 weeks after first opening.
Do not use this medicine after the expiry date which is stated on the carton after Exp. date. The expiry date refers to the last day of that month.
No special precautions for storage.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
6. Contents of the pack and other information
What Silkis contains
The active substance is Calcitriol (3 micrograms per g).
The other excipients are liquid paraffin, white soft paraffin and alpha-tocopherol.
What Silkis looks like and contents of the pack
Silkis is a white, translucent ointment.
This ointment is available on prescription from your doctor in tubes containing 15g, 30g or 100g (not all pack sizes may be marketed).
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Galderma (U.K.) Limited Evergreen House North Grafton Place London England NW1 2DX
PL 10590/0047
Manufacturer
Laboratoires Galderma ZI - Montdésir 74 540 Alby sur Chéran France
This medicinal product is authorised in the Member States of the EEA under the following names:
Czech Republic: Silkis mast
Germany: SILKIS 3 µg/g Salbe
Spain: SILKIS 3 microgramos/g pomada
Finland: Silkis 3 mikrog/g voide
France: SILKIS 3 microgrammes/g, pommade
Ireland: SILKIS 3 micrograms per g ointment
Italy: SILKIS 3 microgrammi per grammo di unguento
Netherlands: SILKIS, zalf 3 microgram/gram
Norway: Silkis 3 mikrogram per g salve
Portugal: SILKIS 3 microgramas por grama de pomada
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Galderma (UK) Ltd.
Tel: +44 (0)300 3035674
This leaflet was last revised in May 2024.
P27889-4
Galderma (U.K) Ltd
Address
Evergreen House North, Grafton Place, London, NW1 2DX, UK